Fontana Elisa, Smyth Elizabeth C, Cunningham David, Rao Sheela, Watkins David, Allum William H, Thompson Jeremy, Waddell Tom, Peckitt Clare, Chau Ian, Starling Naureen
Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK.
Gastric Cancer. 2016 Oct;19(4):1114-1124. doi: 10.1007/s10120-015-0561-5. Epub 2015 Nov 5.
Oesophageal and gastric adenocarcinoma (OGA) treatment remains challenging. Improvements in early diagnosis, staging and management might have contributed to survival prolongation. To examine this hypothesis, we assessed outcomes of resected OGA patients in our institution over 10 years, comparing two time periods, 2001-2005 and 2006-2010.
Records from patients who had undergone surgery with radical intent and follow-up for OGA were retrospectively reviewed. Patients followed up at hospitals other than the Royal Marsden Hospital were excluded. Two different cohorts were identified: patients with oesophageal and type I or type II oesophagogastric junction (OGJ) tumours, and patients with gastric and type III OGJ tumours.
We identified 360 patients: 147 from 2001-2005 and 213 from 2006-2010. The characteristics were comparable across the two time periods. Between 2001-2005 and 2006-2010, the percentage of R0 resections increased (from 67.1 to 81.1 % for proximal tumours and from 76.3 to 95.9 % for gastric and type III OGJ tumours). The mean number of lymph nodes retrieved increased over time. The 5-year overall survival rate increased significantly from 42.3 to 56.6 % for proximal tumours and from 38.8 to 55.3 % for gastric and type III OGJ tumours. Similarly, the disease-free survival rate significantly increased from 34.6 to 53.5 % for proximal tumours and from 35.9 to 51.1 % for gastric and type III OGJ tumours.
This study comprehensively describes the improvement in survival outcomes in a major UK referral centre over a 10-year period, identifying potentially relevant factors such as increased number of R0 resections and higher lymph node yield.
食管和胃腺癌(OGA)的治疗仍然具有挑战性。早期诊断、分期和管理的改善可能有助于延长生存期。为了验证这一假设,我们评估了本机构10年间接受手术切除的OGA患者的预后情况,比较了2001 - 2005年和2006 - 2010年这两个时间段。
对有根治性手术意图并接受OGA随访的患者记录进行回顾性分析。排除在皇家马斯登医院以外的医院进行随访的患者。确定了两个不同的队列:食管及I型或II型食管胃交界(OGJ)肿瘤患者,以及胃及III型OGJ肿瘤患者。
我们共确定了360例患者:2001 - 2005年有147例,2006 - 2010年有213例。两个时间段的患者特征具有可比性。在2001 - 2005年至2006 - 2010年期间,R0切除率有所提高(近端肿瘤从67.1%提高到81.1%,胃及III型OGJ肿瘤从76.3%提高到95.9%)。随着时间的推移,平均获取的淋巴结数量增加。近端肿瘤的5年总生存率从42.3%显著提高到56.6%,胃及III型OGJ肿瘤从38.8%提高到55.3%。同样,近端肿瘤的无病生存率从34.6%显著提高到53.5%,胃及III型OGJ肿瘤从35.9%提高到51.1%。
本研究全面描述了英国一家主要转诊中心10年间生存结局的改善情况,确定了如R0切除数量增加和更高的淋巴结获取量等潜在相关因素。